YUMANITY THERAPEUTICS, INC.

KA | $0.34 100K

(0.0% 1d) (-38.9% 1m) (-92.1% 1y) (0.0% 2d) (0.0% 3d) (-8.1% 7d) (0.76% volume)
Earnings Calendar:
Market Cap: $ 3,727,236
https://www.proteostasis.com
Sec Filling | Patents | 45 employees

(US) Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

treatment dementia biopharma com alzheimer's disease parkinson pharma arm drug candidate system ytx-7739 disease cel cov alzheimer's gen drug discovery parkinson's tiona alzheimer als rapid program therapeutics neurodegenerative pot phase 1 potential tempo sclerosis platform rap alzheimer’s

add to watch list Paper trade email alert is off

Chemomab Therapeutics Ltd - ADR

CMMB | $0.73 30K

Manufacturing

(0.0% 1d) (-8.2% 1m) (-55.2% 1y) (0.0% 2d) (0.0% 3d) (-7.6% 7d) (333.22% volume)
Earnings Calendar:
Market Cap: $ 1,342,932
https://www.chemomab.com
Sec Filling | Patents | 2020 employees

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022.

sclerosis antibody

add to watch list Paper trade email alert is off